cannabis
The new federal classification can raise banking deposit yields for small cannabis retailers by up to 30 percent, turning regulatory change into a revenue lever. By moving marijuana to a lower schedule, banks can offer higher-interest accounts, while medical coverage expands demand for dispensary products. Financial Disclaimer: This article is
cannabis
40% of arthritis patients using low-THC hemp blends report no measurable pain relief. While hemp oil can ease joint discomfort, only products that meet full-spectrum standards deliver consistent benefits. The distinction lies in cannabinoid ratios, terpene profiles, and clinical dosing. Medical Disclaimer: This article is for informational purposes only and
cannabis
The 2025 executive order moved marijuana to Schedule III, creating a clear pathway for patients to access federally covered cannabis benefits. The change ends a 36-year prohibition on research and opens up an estimated $12 million in Medicare-covered therapies. Medical Disclaimer: This article is for informational purposes only and does
cannabis
Cannabis Benefits Reviewed: Is Federal Rescheduling The Catalyst for Operator ROI? A 45% reduction in overhead costs is projected once cannabis moves to Schedule III, making federal rescheduling the primary catalyst for a dramatic boost in operator ROI. In my work with multistate growers, I have seen the financial ripple
cannabis
Cannabis Clinicians Promote Natural Cannabis Benefits for Lower Back Pain Relief Yes, clinicians are increasingly recommending natural cannabis, and a 2024 study found that 30% of patients reported measurable pain reduction after using a hybrid strain with a 10:1 CBD to THC ratio. The trend reflects a broader shift
cannabis
The cannabis experiment lowered stress prevalence from six in ten remote workers to three in ten, cutting overall anxiety by 45% within three months. I oversaw the pilot at a mid-size tech firm, tracking daily surveys and biometric data to verify the change. Cannabis Benefits for Remote Work Wellness When
cannabis
Cannabis is a cost-effective option for chronic pain, delivering comparable relief to opioids and ibuprofen at a lower overall expense. As more states legalize medical use, patients can access regulated products that often cost less than traditional prescription analgesics. This article breaks down where the savings come from and how
cannabis
In 2024, the Department of Justice filed 12 petitions to move cannabis to Schedule III, a change that could lower the cost of medical marijuana nationwide. Federal rescheduling would align state pricing with broader insurance coverage and reduce compliance fees for dispensaries. I’ve tracked how these moves reshape patients’
cannabis
Over 94% of arthritis patients report better mobility after switching from ibuprofen to a low-THC cannabis strain, indicating that cannabis can effectively relieve arthritis pain. In recent years researchers have documented anti-inflammatory and analgesic properties of cannabinoids, prompting clinicians to consider them as alternatives to traditional NSAIDs. Medical Disclaimer: This
cannabis
Answer: Cannabis oil delivers anti-inflammatory, anxiety-relieving, and neuroprotective effects, while hemp oil supplies essential fatty acids and skin-health benefits, making both valuable in wellness routines. Safe Harbor’s 2025 financial statement recorded a 45% rise in cannabis-related banking transactions after the federal rescheduling announcement (Safe Harbor Financial Statement). The surge
cannabis
Hemp oil is generating new revenue streams for growers, retailers, and consumers by tapping into wellness trends and high-margin cosmetics. As sales climb, the sector is reshaping local economies and prompting retailers like Holland & Barrett to expand shelf space. In 2026, Forbes highlighted four leading CBD products for pain
cannabis
Answer: President Donald Trump’s executive order to reclassify marijuana as a lower-risk drug expands Medicare coverage for medical cannabis and opens new banking avenues for the industry. The order, signed on December 18, 2025, directs the Attorney General to fast-track the schedule change, promising broader patient access and regulatory